[HTML][HTML] WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer
Triple-negative breast cancers (TNBCs) are characterized by a poor prognosis and lack of
targeted treatments, and thus, new therapeutic strategies are urgently needed. Inhibitors …
targeted treatments, and thus, new therapeutic strategies are urgently needed. Inhibitors …
[HTML][HTML] PD-L1 blockade by atezolizumab downregulates signaling pathways associated with tumor growth, metastasis, and hypoxia in human triple negative breast …
Triple negative breast cancer (TNBC) is the most aggressive type of breast cancer, which
shows resistance to common breast cancer therapies, as it lacks the expression of the most …
shows resistance to common breast cancer therapies, as it lacks the expression of the most …
Stromal PD-L1 expression is associated with better disease-free survival in triple-negative breast cancer
X Li, CS Wetherilt, U Krishnamurti… - American journal of …, 2016 - academic.oup.com
Objectives: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer,
and there is no approved targeted therapy. We studied the expression of programmed cell …
and there is no approved targeted therapy. We studied the expression of programmed cell …
Characteristics and Spatially Defined Immune (micro) landscapes of Early-stage PD-L1–positive Triple-negative Breast Cancer
Purpose: Programmed death ligand 1 [PD-(L) 1]-targeted therapies have shown modest
survival benefit in triple-negative breast cancer (TNBC). PD-L1+ microenvironments in …
survival benefit in triple-negative breast cancer (TNBC). PD-L1+ microenvironments in …
[HTML][HTML] Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies
WY Sun, YK Lee, JS Koo - Journal of translational medicine, 2016 - Springer
Background To date, there are no effective therapeutic targeting agents for triple-negative
breast cancer (TNBC), and PD-L1 has presented potential as an effective marker of …
breast cancer (TNBC), and PD-L1 has presented potential as an effective marker of …
[HTML][HTML] Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer
M Li, A Li, S Zhou, Y Xu, Y Xiao, R Bi, W Yang - BMC cancer, 2018 - Springer
Background Programmed cell death ligand 1 (PD-L1) is a potential predictive biomarker of
the response to anti-PD-L1/anti-programmed cell death 1 (PD-1) therapy in multiple cancers …
the response to anti-PD-L1/anti-programmed cell death 1 (PD-1) therapy in multiple cancers …
[HTML][HTML] PD-L1 silencing inhibits triple-negative breast cancer development and upregulates T-cell-induced pro-inflammatory cytokines
Triple-negative breast cancer (TNBC) is an invasive tumor with a high incidence of distant
metastasis and poor prognosis. In TNBC cells, high PD-L1 expression can induce an …
metastasis and poor prognosis. In TNBC cells, high PD-L1 expression can induce an …
[HTML][HTML] PD-L1 tumor-intrinsic signaling and its therapeutic implication in triple-negative breast cancer
C Chen, S Li, J Xue, M Qi, X Liu, Y Huang, J Hu… - JCI insight, 2021 - ncbi.nlm.nih.gov
Although the immune checkpoint role of programmed death ligand 1 (PD-L1) has been
established and targeted in cancer immunotherapy, the tumor-intrinsic role of PD-L1 is less …
established and targeted in cancer immunotherapy, the tumor-intrinsic role of PD-L1 is less …
PD-L1 expression in triple-negative breast cancer
EA Mittendorf, AV Philips, F Meric-Bernstam… - Cancer immunology …, 2014 - AACR
Early-phase trials targeting the T-cell inhibitory molecule programmed cell death ligand 1
(PD-L1) have shown clinical efficacy in cancer. This study was undertaken to determine …
(PD-L1) have shown clinical efficacy in cancer. This study was undertaken to determine …
[HTML][HTML] Wnt modulates MCL1 to control cell survival in triple negative breast cancer
L Yang, AA Perez, S Fujie, C Warden, J Li, Y Wang… - BMC cancer, 2014 - Springer
Background Triple negative breast cancer (TNBC) has higher rates of recurrence and distant
metastasis, and poorer outcome as compared to non-TNBC. Aberrant activation of WNT …
metastasis, and poorer outcome as compared to non-TNBC. Aberrant activation of WNT …